Floppy eyelid syndrome and obstructive sleep apnea: a unique phenotype?

Introduction Floppy eyelid syndrome (FES) is an underdiagnosed condition stereotypically found in obese, middle-aged men, characterized by a lax eyelid tarsus which readily everts without excess mechanical manipulation. Obstructive sleep apnoea (OSA) is the most frequently reported comorbidity in patients suffering from FES. The aim of this study was to determine whether or not individuals with FES present with distinct anthropometric characteristics in comparison to patients without FES suspected of having OSA. Methods A retrospective case-control study in which FES patients and controls all referred for investigation of suspected OSA, matched for sex, ethnicity, residential location, age (+/- 2 years), date of sleep study (+/- 1 month), and type of sleep study were compared for anthropometric, comorbidity, and sleep data differences. Results OSA prevalence and severity, assessed by apnoea-hypopnea index (AHI), revealed no significant differences between patients with FES (n = 39) and those without (n = 75), (85% vs 88%, p = 0.91 and 31.9 +/- 28.7 vs 28.5 +/- 16.6, p = 0.81 respectively), despite patients with FES being more obese (p = 0.02). Patients with FES had significantly lower Epworth sleepiness scale (ESS) scores after treatment with CPAP (5.3 +/- 4.1 vs 9.4 +/- 5.0, p = 0.028). Patients with FES exhibited increased prevalence of hernias (15% vs 4%, p = 0.032), dermatological (41% vs 17%, p = 0.006) and rheumatological (15% vs 3%, p = 0.012) comorbidities. Conclusion FES patients appear to exhibit a distinct phenotype with increased prevalence of comorbidities related to matrix metalloproteinase dysfunction and significant improvement of daytime hypersomnolence with continuous positive airway pressure (CPAP) treatment.

Automated summary

This study compares individuals with floppy eyelid syndrome (FES) to individuals suspected of having obstructive sleep apnea (OSA) without FES, and finds that FES patients have a higher prevalence of comorbidities related to matrix metalloproteinase dysfunction, and significant improvement in daytime hypersomnolence with continuous positive airway pressure (CPAP) treatment.